ACAD News & Events

Acadia Pharmaceuticals announced the appointment of Carl Segerstrom as Chief People Officer. Carl will lead the company's global people and culture strategy, supporting its next phase of growth as a leading neurological and rare disease company focused on advancing therapies for patients with significant unmet needs. He will serve as a member of Acadia's executive leadership team. Most recently, he served as Senior Vice President, Human Resources at Merck's Human Health Division, supporting a $50+ billion global business spanning 80 countries.

The CHMP last week issued a positive re-examination opinion recommending EU approval for Acadia's DAYBU, or trofinetide, after narrowing the label to neurobehavioral symptoms of Rett syndrome and restricting the age range, with the decision based on Phase 3 LAVENDER trial results showing clinically meaningful improvements, H.C. Wainwright tells investors in a research note. The European Commission will now make the final decision, and potential orphan exclusivity could provide up to 10 years of protection if upheld, the firm, which has a Buy rating and $37 price target on Acadia shares, says.